Teriparatide as a Chondroregenerative Therapy in OA
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate teriparatide (TP) as a chondroregenerative therapy
for human knee osteoarthritis (OA). The central hypothesis to be tested is that TP supports
structural modification of the joint and improves biomarker, functional and patient-reported
measures of knee OA.
Phase:
Phase 2
Details
Lead Sponsor:
Michael Zuscik Mike Zuscik
Collaborators:
Duke University Eli Lilly and Company Milton S. Hershey Medical Center University of Rochester